Variantyx

A patient presents with signs of hereditary neuropathy. Is it CMT? HNPP? Something else? 🤔

Traditional sequential genetic tests can miss key variants.

Our Genomic Unity® Neuropathies Analysis uses the power of whole genome sequencing to provide the most comprehensive testing available. This test:
✔️Targets 103 genes linked to inherited neuropathies
✔️Automatically reflexes to full genome analysis if initial findings are inconclusive
✔️Detects variants of all sizes - from single base changes to complex structural changes including CNVs and repeat expansions in RFC1, ZFHX3 and more.

Technology matters. Choose wisely. Choose Variantyx.

Learn more ➡️ https://ow.ly/Bn9n50VR6Xf

Think all epilepsy genetic tests are the same? Think again. Our whole genome technology offers unmatched resolution and more variant types with just one sample. Discover the Variantyx difference at https://ow.ly/54rX50UWVp5

Exciting news! Our Lightning rapid genome test is now available for patients of all ages. Choose from neonatal, pediatric and standard analysis offerings. All three are lightning fast, ensuring timely answers to guide medical management. Learn more here -> https://www.variantyx.com/products-services/rare-disorder-genetics/rapid-genome/

Today we celebrate genetic counselors everywhere! Thank you for the support you provide to patients and their families.

Check out this week's GenomeWeb article featuring Genomic Unity® 2.0 combined short and long-read genome sequencing 🧬 https://www.genomeweb.com/sequencing/variantyx-combines-long-nanopore-short-illumina-reads-rare-disease-whole-genome

With treatment options available for , comprehensive identification of MECP2 variants through testing has become even more important. Download our case study describing a partial exon MECP2 deletion to see why Seeing More with Variantyx testing makes a difference 🔎 https://ow.ly/gOCQ50TMKWa

Watch to see how Genomic Unity® whole genome testing made a Segawa syndrome diagnosis following multiple negative tests using other technologies ▶️ https://ow.ly/jhne50TIUNW

awareness month is off to a positive start with the FDA’s recent approval of two Type C treatments: Aqneursa and Miplyffa. For the most comprehensive analysis of NPC1 and NPC2 genes available, choose Genomic Unity testing. Learn more about the Variantyx difference ➡️ https://www.variantyx.com/patients/the-variantyx-difference/

Thanks to the comprehensive analysis power of IriSight™ testing, we find that ~6% of prenatal cases result in a dual diagnosis. Download our latest prenatal case study to see how a mix of small sequence changes and single exon deletions was uniquely detected in a single test 👉 https://ow.ly/K3lj50T8ZkU

Here at Variantyx genomes are the standard, and have been for 10 years. Curious to see what the next evolution of genomic testing looks like? Stay tuned for an exciting revelation at !